Back to top
more

Nivalis Therapeutics, Inc. (ALPN)

(Delayed Data from NSDQ)

$6.24 USD

6.24
7,474

-0.08 (-1.27%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ALPN]

Reports for Purchase

Showing records 61 - 80 ( 156 total )

Industry: Medical - Drugs

Record: 61

06/02/2022

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 62

06/02/2022

Daily Note

Pages: 6

First Look at ALPN-303; Early Profile Suggests Best in Class Potential

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 63

06/01/2022

Company Report

Pages: 88

Two Birds, One Stone; Data Highlight ALPN-303''s Potential As a Dual BAFF/APRIL Antagonist

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 64

05/31/2022

Daily Note

Pages: 11

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 65

05/31/2022

Industry Report

Pages: 11

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 66

05/29/2022

Industry Report

Pages: 17

2022 Abstract Roundup For Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 67

05/24/2022

Daily Note

Pages: 5

NEON-2 Receives Green Light From the FDA to Push On; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 68

05/24/2022

Daily Note

Pages: 4

NEON-2 Back on Track

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 69

05/17/2022

Daily Note

Pages: 14

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 70

05/17/2022

Company Report

Pages: 6

Q1 Financials; First Look at ALPN-303 in Clinic at EULAR

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 71

05/13/2022

Company Report

Pages: 8

1Q22 Results; Strong Cash Supporting Pipeline; NEON-1 Open for Enrollment, ALPN-303 Initial Data Mid-2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 72

04/28/2022

Industry Report

Pages: 7

ASCO 2022 Abstract Titles for Covered Companies

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 73

04/13/2022

Daily Note

Pages: 6

Robust Davoceticept Dose-Escalation Dataset Supports Next Steps

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 74

04/13/2022

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 75

04/13/2022

Company Report

Pages: 8

NEON-1 Illuminates Davoceticept''s Way Forward at AACR

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 76

04/05/2022

Company Report

Pages: 10

Davoceticept?s 3x1 Strategy Corroborates Promising Preclinical Efficacy Ahead of NEON-1 Readout at AACR

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 77

03/21/2022

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 78

03/21/2022

Company Report

Pages: 6

Q4 Financials; Updated Look at Davoceticept Ahead at AACR

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 79

03/18/2022

Company Report

Pages: 8

2021 Results; NEON-1 Update at AACR Kicks Off a Year of Anticipated News Across All Programs

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 80

03/09/2022

Industry Report

Pages: 10

AACR 2022 Abstract Roundup For Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party
// eof